Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Wall Street is bullish on Viking Therapeutics (VKTX) due to successful clinical trials of its weight loss drug VK2735, which showed significant weight loss in patients. Billionaires Jeff Yass and Israel Englander have increased their stakes in the company. VK2735, a dual GLP-1 and GIP receptor agonist, outperformed competitors like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. Viking Therapeutics also has a promising drug, VK2809, for metabolic dysfunction-associated steatohepatitis (MASH). Upcoming catalysts include phase 3 trials for VK2735 and a phase 2 study of oral VK2735. Despite potential risks, Viking Therapeutics is considered a high-risk, high-reward investment.
Reference News
The weight-loss drug market is booming, with Viking Therapeutics emerging as a contender. VKTX stock is attracting billionaire investors and analysts predict significant gains. Viking's VK2735, a dual GLP-1/GIP agonist, is set to skip to Phase 3, challenging industry giants like Eli Lilly and Novo Nordisk.
Wall Street is bullish on Viking Therapeutics (VKTX) due to successful clinical trials of its weight loss drug VK2735, which showed significant weight loss in patients. Billionaires Jeff Yass and Israel Englander have increased their stakes in the company. VK2735, a dual GLP-1 and GIP receptor agonist, outperformed competitors like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. Viking Therapeutics also has a promising drug, VK2809, for metabolic dysfunction-associated steatohepatitis (MASH). Upcoming catalysts include phase 3 trials for VK2735 and a phase 2 study of oral VK2735. Despite potential risks, Viking Therapeutics is considered a high-risk, high-reward investment.
The weight-loss drug market is booming, with Viking Therapeutics (VKTX) emerging as a key player, challenging giants like Eli Lilly (LLY) and Novo Nordisk (NVO). VKTX's VK2735, a dual GLP-1/GIP agonist, showed strong results in early trials, with oral and injectable forms. Analysts predict significant growth, with JPMorgan advising investors to buy VKTX stock ahead of a November catalyst event.